Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.

@article{Kumar2018AripiprazoleAF,
  title={Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.},
  author={A. Kumar and H. Singh and Amrita Mishra and A. Mishra},
  journal={Current drug discovery technologies},
  year={2018}
}
  • A. Kumar, H. Singh, +1 author A. Mishra
  • Published 2018
  • Medicine
  • Current drug discovery technologies
    • OBJECTIVE Aripiprazole,a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of Aripiprazole. DEVELOPMENT Aripiprazole, under development by Otsuka Pharmaceutical, was approved by the U.S. Food and Drug Administration (USFDA) in the end months of 2002 to with an aim to treat patients with… CONTINUE READING
    View on PubMed
    doi.org

    References

    SHOWING 1-10 OF 37 REFERENCES
    Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    • 536
    • PDF
    A review of aripiprazole long-acting injection
    • 12
    Aripiprazole, a Novel Atypical Antipsychotic Drug
    • 70
    Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    • 115
    • PDF
    Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.
    • 45
    • PDF
    Aripiprazole: from pharmacological profile to clinical use
    • 44
    • PDF
    Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    • 529
    • PDF
    Quantitative structure – activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment
    • 12
    Syk and Src‐targeted anti‐inflammatory activity of aripiprazole, an atypical antipsychotic
    • 23
    Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
    • 62
    • PDF